KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Gains from Sales and Divestitures: 2019

Historic Gains from Sales and Divestitures for Novavax (NVAX) over the last 1 years, with Dec 2019 value amounting to $72,637.

  • Novavax's Gains from Sales and Divestitures rose 976.33% to $781,812 in Q3 2020 from the same period last year, while for Sep 2020 it was $781,812, marking a year-over-year increase of 976.33%. This contributed to the annual value of $72,637 for FY2019, which is N/A change from last year.
  • Novavax's Gains from Sales and Divestitures amounted to $72,637 in FY2019.
  • Novavax's 5-year Gains from Sales and Divestitures high stood at $72,637 for FY2019, and its period low was $72,637 during FY2019.
  • Over the past 1 years, Novavax's median Gains from Sales and Divestitures value was $72,637 (recorded in 2019), while the average stood at $72,637.